The Genetic Epidemiology group is seeking two highly motivated postdoctoral scientists to participate in the design and analysis of large genomic datasets in order to identify and validate drug targets for neurodegenerative/neuropsychiatric diseases such as Alzheimer’s, Parkinson’s, schizophrenia and ALS.
The goal of the Genetic Epidemiology group within Research and Early Development is to translate human genetic discoveries into testable therapeutic hypotheses. We leverage large-scale genetic, genomic and clinical datasets to support target discovery and validation for Biogen’s drug discovery research teams and clinical programs. Biogen has made substantial investments in external partnerships and collaborations, and a focus of the team will be how to best leverage these resources. These collaborations include the UK Biobank Life Sciences Consortium (that by 2020 will have generated whole-exome sequencing data on 500,000 UK Biobank participants), FinnGen (a precompetitive partnership generating genotypes on 500,000 Finns with longitudinal health data), as well as other public and proprietary resources, including clinical trial, disease-specific whole-genome/exome sequencing and large-scale QTL data, to help initiate novel and enhance existing drug development programs.
The aims of the research project include but are not limited to:
At Biogen, we consider these activities pre-competitive and therefore encourage the dissemination of findings at scientific conferences and journal publications. The candidates will join an experienced team of statistical geneticists and have opportunities to closely collaborate with the broader Biogen R&D community. They will be mentored by Drs. Jimmy Liu, Chia-Yen Chen and Heiko Runz.
Strong background and knowledge of quantitative/statistical genetics theory and applications
PhD in statistical genetics, genetic epidemiology, genomics, human genetics, statistics, computer science, bioinformatics or related field with 0-3 years of postdoctoral training.